Pyxis Oncology (NASDAQ: PYXS) presented updated clinical data on its investigational drug micvotabart pelidotin at a webcast held on September 9, 2026, following the initial announcement on September 8.
Micvotabart pelidotin is an antibody-drug conjugate that targets the extradomain-B of fibronectin, a protein component of the tumor extracellular matrix. The company provided detailed analyses of patients receiving 5.4 mg/kg intravenously once every three weeks, with doses equivalent to or below a stated dose cap.
The data focused on patients with recurrent or metastatic head and neck squamous cell carcinoma — the monotherapy evaluation encompassed second-line treatment and beyond. An ongoing Phase 1 study and expansion trial supplied the updated efficacy and safety results.
The antibody-drug conjugate is also being evaluated in combination with Merck’s pembrolizumab in a Phase 1/2 clinical study for recurrent and metastatic head and neck squamous cell carcinoma as well as other solid tumors.
Alan L. Ho, M.D., Ph.D., chief of the head and neck oncology service and attending medical oncologist at Memorial Sloan Kettering Cancer Center, was associated with the clinical program.
The U.S. Food and Drug Administration granted fast track designation to micvotabart pelidotin for adult patients with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed after platinum-based chemotherapy and anti-PD-(L)1 therapy.
An archived version of the webcast became available following the event on the company’s website.
